Institution statistics

INSTITUT GUSTAVE ROUSSY - France 

Ranking results:

Past rankings:
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:400-500
Total Project Funding:400-500
Total Project Funding per Partner:300-400
Total Number of Projects:65
Networking Rank (Reputation):500-600
Networking Rank (Reputation):500-600
Partner Constancy:46
Project Leadership Index:75
Diversity Index:18
2011
Criterium:Position:
Overall Score:800-900
Total Project Funding:100-200
Total Project Funding per Partner:200-300
Total Number of Projects:200-300
Networking Rank (Reputation):200-300
Partner Constancy:100-200
Project Leadership Index:600-700
Diversity Index:> 1000
2009
Criterium:Position:
Overall Score:> 1000
Total Project Funding:600-700
Total Project Funding per Partner:700-800
Total Number of Projects:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:600-700
Project Leadership Index:500-600
Diversity Index:> 1000
2008
Criterium:Position:
Overall Score:400-500
Total Project Funding:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:600-700
Project Leadership Index:500-600
Diversity Index:500-600
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding:400-500
Total Project Funding per Partner:300-400
Total Number of Projects:600-700
Networking Rank (Reputation):> 1000
Partner Constancy:400-500
Project Leadership Index:400-500
Diversity Index:> 1000
Ranking timeline:

European project participation (2000-01-01 - 2017-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 49
As coordinator: 5
As participant: 42
Sole participant: 2
Coordinator / Participant Ratio: 0.12*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2017 0 7.370.000 491.333 1
2016 0 1.500.000 1.500.000 1
2015 0 7.476.725 699.150 2
2013 2.998.355 11.662.081 1.750.320 1 2
2012 268.555 25.088.618 2.570.250 1 5
2011 0 63.192.794 3.586.820 11
2009 0 15.551.032 940.021 2
2008 5.228.003 279.931 611.992 1 1
2007 0 11.692.460 789.960 2
2006 3.415.414 9.432.600 759.663 1 1
2005 0 24.052.468 1.092.790 5
2004 0 21.493.900 617.253 5
2003 892.993 0 148.832 1
2002 1.909.090 3.875.479 706.653 1 2
2001 75.000 1.815.000 280.250 1 2
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
KAROLINSKA INSTITUTE15
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM10
INSTITUT CURIE10
UNIVERSITY OF BIRMINGHAM10
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE9
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER8
INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL7
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD7
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN6
UNIVERSITY OF NEWCASTLE UPON TYNE6
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM5
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE5
CHARITE UNIVERSITAETSMEDIZIN BERLIN5
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III5
ISTITUTO GIANNINA GASLINI5
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI5
LEIDEN UNIVERSITY MEDICAL CENTER5
UNIVERSITA DEGLI STUDI DI TORINO5
UNIVERSITY COLLEGE LONDON5
ACADEMISCH ZIEKENHUIS LEIDEN4
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS4
DANISH CANCER SOCIETY4
DEUTSCHES KREBSFORSCHUNGSZENTRUM4
GSF FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT4
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE4
INSTITUTE OF ONCOLOGY LJUBLJANA4
ISTITUTO SUPERIORE DI SANITA4
LUNDS UNIVERSITET4
MEDICAL RESEARCH COUNCIL4
STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS4
UNIVERSITA DEGLI STUDI DI PADOVA4
CANCER RESEARCH UK3
ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM3
EUROPEAN CANCER ORGANISATION3
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL3
INSTITUT JULES BORDET3
IPSOGEN SAS3
ISTITUTO EUROPEO DI ONCOLOGIA3
KATHOLIEKE UNIVERSITEIT LEUVEN3
MEDICAL UNIVERSITY OF GDANSK3
MEDIZINISCHE UNIVERSITAET WIEN3
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS3
ST ANNA KINDERKREBSFORSCHUNG3
STICHTING KATHOLIEKE UNIVERSITEIT3
STICHTING KATHOLIEKE UNIVERSITEIT MORE PARTICULARLY RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTRE3
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE3
UNIVERSITA CATTOLICA DEL SACRO CUORE3
UNIVERSITA DEGLI STUDI DI FIRENZE3
UNIVERSITA DEGLI STUDI DI MILANO BICOCCA3
UNIVERSITY OF LEEDS3
UPPSALA UNIVERSITET3
WESTFAELISCHE WILHELMSUNIVERSITAET MUENSTER3
AARHUS UNIVERSITY HOSPITAL2
ALMA CONSULTING GROUP SAS2
ARTTIC2
BENGURION UNIVERSITY OF THE NEGEV2
CENTRE ANTICANCEREUX LEON BERARD2
CENTRE NATIONAL FRANCOIS BACLESSE2
EBERHARD KARLS UNIVERSITAET TUEBINGEN2
ECOLE NORMALE SUPERIEURE DE CACHAN2
ENTE PER LE NUOVE TECNOLOGIE L'ENERGIA E L'AMBIENTE2
EUROPEAN MOLECULAR BIOLOGY LABORATORY2
EUROPEAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY2
FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS2
FUNDACIO CENTRE DE RECERCA EN EPIDEMIOLOGIA AMBIENTAL CREAL2
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALLHEBRON2
FUNDACION DE INVESTIGACION DEL CANCER DE LA UNIVERSIDAD DE SALAMANCA2
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA2
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O2
HET NEDERLANDS KANKER INSTITUUT2
HOSPITAL CLINIC PROVINCIAL DE BARCELONA2
INSTITUT BERGONIE2
INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO2
ISTITUTO ORTOPEDICO RIZZOLI2
JUSTUS LIEBIG UNIVERSITAET GIESSEN2
KEOCYT SAS2
KING'S COLLEGE LONDON2
MASARYKOVA UNIVERZITA2
MEDIZINISCHE HOCHSCHULE HANNOVER2
QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON2
RAY SEARCH LABORATORIES AB2
RUPRECHT KARLS UNIVERSITAET HEIDELBERG2
SARCOMA PATIENTS EURONET EV2
SEMMELWEIS EGYETEM2
SIOP EUROPE2
STICHTING ANTONI VAN LEEUWENHOEK ZIEKENHUIS2
STUDIECENTRUM VOOR KERNENERGIE2
TECHNICAL UNIVERSITY OF MUNICH2
THE CHRISTIE NHS FOUNDATION TRUST2
THE NETHERLANDS CANCER INSTITUTE2
THE UNIVERSITY OF LIVERPOOL2
THE UNIVERSITY OF MANCHESTER2
UNIVERSITA DEGLI STUDI DI MILANOBICOCCA2
UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA2
UNIVERSITAET ZUERICH2
UNIVERSITAETSKLINIKUM HAMBURG EPPENDORF2
UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ2
UNIVERSITE CATHOLIQUE DE LOUVAIN2
UNIVERSITE CLAUDE BERNARD LYON 12
UNIVERSITE DE PARISSUD XI2
Constancy:

Total number of partners:823

Partner loyalty:
Frequent Partner: (> 2 projects): 244
Rare Partner: 579

Frequent / Rare Partner Ratio: 0.42

Diversity:

Categories:
Category:No:
BIOLOGICAL SCIENCES35
RTD HORIZONTAL TOPICS19
SOCIAL AND ECONOMIC CONCERNS5
PROTECTING MAN AND HIS ENVIRON5
ENERGY4
INDUSTRY AND TECHNOLOGY3

Project overview:

Start dateProjectacronymrolefundingpartners
2017-05-18ITCC Pediatric Preclinical POC Platform (ITCC-P4) ITCC-P4participant7.370.00015
2016-12-01Resistance mechanisms to tyrosine kinase inhibitors in solid tumors TKI resistanceparticipant1.500.0001
2015-12-01Training Network for the Immunotherapy of Cancer IMMUTRAINparticipant3.627.5259
2015-09-01ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer ALKATRASparticipant3.849.20013
2013-10-01EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma EECparticipant5.697.83120
2013-06-01Mutanome Engineered RNA Immuno-Therapy MERITparticipant5.964.2505
2013-03-01WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients WINTHERcoordinator2.998.35511
2012-11-01Non-Invasive Optical Biopsy for Cancer Assessment using ultra high resolution Full-Field Optical Coherence Tomography CAReIOCAparticipant3.099.4815
2012-10-01Rational molecular Assessments and Innovative Drug Selection RAIDSparticipant5.999.64216
2012-09-01Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients CTCTRAPparticipant6.000.00012
2012-08-01Genetic epidemiological investigation into the association between endometriosis and cutaneous melanoma MELENDO2coordinator268.5551
2012-04-01Biomaterials for Tracheal Replacement in Age-related Cancer via a Humanly Engineered Airway BIOtracheaparticipant3.999.30013
2012-02-01Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer RESPONSIFYparticipant5.990.19512
2011-12-01STRENGTHENING COOPERATION IN MOLECULAR BIOMEDICINE BETWEEN EU AND UKRAINE COMBIOMparticipant455.4993
2011-12-01European Clinical trials in Rare Sarcomas within an integrated translational trial network EUROSARCparticipant5.953.83218
2011-10-01Cognitive and Cerebrovascular Effects Induced by Low Dose Ionising Radiation CEREBRADparticipant2.999.51712
2011-10-01Cardiovascular Risk from Exposure to Low-dose and Low-dose-rate Ionizing Radiation PROCARDIOparticipant2.998.38713
2011-04-01Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE ARTFORCEparticipant5.994.71514
2011-02-01PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies PanCareSurFupparticipant5.993.69517
2011-01-01Predicting individual response and resistance to VEGFR/mTOR pathway therapeutic intervention using biomarkers discovered through tumour functional genomics PREDICTparticipant5.841.00914
2011-01-01A European Platform for Translational Cancer Research EUROCANPLATFORMparticipant11.998.45428
2011-01-01Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis CURELUNGparticipant2.965.74911
2011-01-01European Network for the Study of Adrenal Tumours - Structuring clinical research on adrenal cancers in adults ENS@T-CANCERparticipant5.993.97816
2011-01-01EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS ENCCAparticipant11.997.95934
2009-07-01Integrated micro-nano-opto fluidic systems for high-content diagnosis and studies of rare cancer cells CAMINEMSparticipant3.551.1439
2009-01-01Understanding inflammation-associated tumorigenesis for the rational design of novel anti-cancer therapeutic strategies INFLA-CAREparticipant11.999.88922
2008-09-01Oral off-patent oncology drugs for kids 03Kcoordinator5.228.0039
2008-09-01Prospective cohort studies of children with substantial medical diagnostic exposure CHILD-MED-RADparticipant279.9319
2007-03-01Colon and breast cancer diagnostics COBREDparticipant2.985.1029
2007-02-01Molecular mechanisms underlying chemotherapy resistance, therapeutic escape, efficacy and toxicity CHEMORESparticipant8.707.35819
2006-11-01Selecting and validating drug targets from the human kinome for high risk pediatric cancers KIDSCANCERKINOMEcoordinator3.415.41411
2006-02-01CONnective TIssue CAncers NETwork to integrate European Experience in Adults and Children CONTICANETparticipant9.432.60021
2005-12-01European Prospective Investigation into Cancer, Chronic Diseases, Nutrition and Lifestyle EPICparticipant999.74527
2005-12-01Genetic and environmental determinants of melanoma: translation into behavioural change GENOMELparticipant10.452.72322
2005-10-01Feasibility Study for Coordination of National Cancer Research Activities EUROCAN+PLUSparticipant3.000.00017
2005-06-01Radiation exposures at an early age: impact of genotype on breast cancer risk GENE-RAD RISKparticipant2.000.00012
2005-01-01Dendritic cells for novel immmunotherapies DC-THERAparticipant7.600.00032
2004-07-01European Mantle Cell Lymphoma Network: Tranlational determination of molecular prognostic factors and pharmacogenomics in a European interdisciplinary collaboration EUROPEAN MCL NETWORKparticipant2.493.90018
2004-05-01METHODS AND ADVANCED EQUIPMENT FOR SIMULATION AND TREATMENT IN RADIO-ONCOLOGY MAESTROparticipant025
2004-03-01Translating molecular knowledge into early breast cancer management: building on the BIG (Breast International Group) network for improved treatment tailoring - TRANS-BIG TRANS-BIGparticipant7.000.00044
2004-03-01Molecular Imaging for Biologically Optimised Cancer Therapy BIOCAREparticipant6.000.00021
2004-01-01Strengthen and develop scientific and technological excellence in research and therapy of leukemia (CML, AML, ALL, CLL, MDS, CMPD) by integration of the leading national leukemia networks and their interdisciplinary partner groups in Europe EUROPEAN LEUKEMIANETparticipant6.000.000177
2003-01-01European standard operating procedures for electrochemotherapy and electrogenetherapy ESOPEcoordinator892.9936
2002-12-01Interplay among mitochondria and p53 family proteins during apoptosis induced by dna damage - a new strategy for cancer therapy IMPALEDparticipant1.983.5477
2002-11-01European society of paediatric oncology neuroblastoma research network SIOPEN-R-NETparticipant1.891.93218
2002-01-01Biochemical and functional characterization of antigen presenting cell derived-exosomes: the design of a cell free cancer vaccine EXOSOMEcoordinator1.909.0906
2001-09-01Congress to develop consensus among network partners on the concept : "global cancer management : towards a european model." coordinator75.0001
2001-03-01Oxidative stress and chronic diseases : exocyclic dna adducts as markers for disrupted genomic integrity and risk OXEXRISKparticipant950.0008
2001-01-01Enabling Best Practices For Oncology BEPROparticipant865.00010

Alias institution names:
  • INSTITUT GUSTAVE ROUSSY

Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum
Ads: